Ensign Peak Advisors, Inc Alx Oncology Holdings Inc Transaction History

Ensign Peak Advisors, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$5.89 - $19.46 $742,622 - $2.45 Million	-126,082 Reduced 98.94%	1,350 $11,000
Q4 2021 Feb 11, 2022	SELL	$21.49 - $74.4 $4.69 Million - $16.2 Million	-218,052 Reduced 63.11%	127,432 $2.74 Million
Q3 2021 Nov 12, 2021	SELL	$52.51 - $80.91 $1.65 Million - $2.54 Million	-31,381 Reduced 8.33%	345,484 $25.5 Million
Q2 2021 Aug 13, 2021	BUY	$52.2 - $75.23 $2.12 Million - $3.05 Million	40,566 Added 12.06%	376,865 $20.6 Million
Q1 2021 May 12, 2021	BUY	$62.84 - $87.68 $19.4 Million - $27.1 Million	309,255 Added 1143.53%	336,299 $24.8 Million
Q4 2020 Feb 12, 2021	BUY	$34.11 - $112.26 $922,470 - $3.04 Million	27,044 New	27,044 $2.33 Million

101

39.7M

134K

17.4K

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $66M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.